Evaluating eating behaviors and psychological state in noncommunicable diseases treatment using GLP-1 receptor agonists

Evaluating eating behaviors and psychological state in noncommunicable diseases treatment using GLP-1 receptor agonists - GLP-1 receptor agonists: effects on eating and psychology

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055091

Enrollment

Registered

2024-07-28

Start date

2024-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, obesity with type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with obesity or obesity-related type 2 diabetes scheduled to start GLP-1 receptor agonists (liraglutide, lixisenatide, dulaglutide, semaglutide, tirzepatide). 2. Those who can respond to EMA via smartphone in their daily life. 3. Those who own a smartphone. 4. Those who have received sufficient explanation about the study, fully understand it, and have freely given their consent to participate.

Exclusion criteria

Exclusion criteria: 1.Individuals who are unable to utilize the study app 2.Individuals deemed inappropriate to participate in the study by physician judgement

Design outcomes

Primary

Measure	Time frame
Changes in psychological assessment scales 1 to 3 months after the start of GLP-1 receptor agonists administration	—

Secondary

Measure	Time frame
The relationship between changes in psychological assessment scales and medical record information	—

Countries

Japan

Contacts

Public ContactAika Miya

Hokkaido University Hospital Diabetes and Endocrinology

miyaaika@huhp.hokudai.ac.jp+81-11-706-5915

Outcome results